Multivalent Immunogenic Vaccines for Treating Prostate and Breast Cancer

The development of more targeted means of treating cancer is vital. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of antibodies or T cells that recognize the peptide. If the peptide is from a protein found selectively on/in cancer cells, those antibodies or T cells can trigger the death of those cancer cells without harming non-cancer cells. This can result in fewer side effects for the patient.

TARP (T cell receptor gamma alternate reading frame protein) is a protein that is selectively expressed on the cells of about 95% of prostate cancers and about 50% of breast cancers. This invention concerns the identification of a combination of seven (7) immunogenic peptides within TARP and their use to create an anti-cancer immune response in patients. The vaccine includes two synthetic 9-mer TARP peptides covered by E-116-2003 and five additional 20-mer peptides overlapping by 10-mer and covering the entire 58-residue sequence of the TARP protein.  Because the additional peptides are overlapping, they can stimulate both humoral and cellular killing responses.  By introducing these seven peptides into a patient, an immune response against these cancer cells can be initiated by the peptides, resulting in treatment of the cancer.  

NCI seeks licensees or co-development partners to commercialize this invention.

Potential Commercial Applications: Competitive Advantages:
  • Peptides can be used as vaccines to induce an immune response against cancer.
  • Treatment of any cancer associated with increased or preferential expression of TARP.
  • Specific diseases include breast cancer and prostate cancer.
  • Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients
  • Not restricted to tissue type
  • Use of multiple peptides permits production of a more thorough complement of T cells against the antigen

Development Stage:
Pre-clinical (in vivo)


Jay Berzofsky (NCI)  ➽ more inventions...

Masaki Terabe (NCI)  ➽ more inventions...

Lauren Wood (NCI)  ➽ more inventions...

Brenda Roberson (NCI)  ➽ more inventions...

Intellectual Property:
US Application No. 61/915,948
Foreign Filed Application No. PCT/US2014/070144
US Application No. 15/102,996
Canada Application No. 2932248
European Application No. 14831120.2
Japan Application No. 2016-538101
Australia Application No. 2014361788

Wood L, et al. PMC5007958
Epel M et al. PMID 18446790
Oh S et al. PMID 15059918

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-047-2014
Updated: Apr 7, 2020